Status:
COMPLETED
Non-Interventional Registry Study to Evaluate the Effectiveness of TheraSphere® in the Treatment of Hepatocellular Carcinoma (HCC)
Lead Sponsor:
Boston Scientific Corporation
Collaborating Sponsors:
Biocompatibles UK Ltd
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this registry study is to gather effectiveness, QoL, safety and procedural information on TheraSphere® for the treatment of participants with Hepatocellular Carcinoma (HCC), Intrahepati...
Detailed Description
TheraSphere is a radioembolic therapeutic device used in the treatment of liver cancers. The goal of the registry study is to collect prospectively: participant description, treatment goal, treatment ...
Eligibility Criteria
Inclusion
- Inclusion:
- Participant has received a reimbursed dose of TheraSphere®
- Participant does not oppose to the collection of his/her medical personal data
- Exclusion:
- Participant has opposed to data collection
- Participant has not received a reimbursed dose of TheraSphere® (free of charge dose)
Exclusion
Key Trial Info
Start Date :
March 13 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
1247 Patients enrolled
Trial Details
Trial ID
NCT04069468
Start Date
March 13 2019
End Date
December 31 2024
Last Update
July 23 2025
Active Locations (37)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France
2
CHU, Angers
Angers, France
3
CHU Jean Minjoz
Besançon, France
4
Institut Bergonié
Bordeaux, France, 33000